Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AMT-676 plus 5-fluorouracil, leucovorin, and bevacizumab or cetuximab in advanced colorectal cancer
CTR20260849Phase 2Active
- Sponsor
- PuZhong Discovery
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-676 in colorectal cancer (CRC), sponsored by PuZhong Discovery. Started Apr 2026; status: active.
02
Drugs
AMT-676
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260849.